MedTrace Logo

Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine

NCT05158855 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-06-30

No results posted yet for this study

Summary

This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis spore extract which contain Spike protein of the SARS-COV2 on the spore coat.

Conditions

  • COVID-19 Pandemic

Interventions

DIETARY_SUPPLEMENT

Bacillus subtilis spore extract

Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronavirus. This product could have a vaccine like activity within the intestinal environment.

Sponsors & Collaborators

  • DreamTec Cytokine Limited

    collaborator UNKNOWN

  • DreamTec Research Limited

    lead INDUSTRY

Principal Investigators

  • WAI YEUNG KWONG, PhD · DreamTec Cytokine Limited

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-04-20
Completion
2022-04-30

Countries

  • Macau

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05158855 on ClinicalTrials.gov